Your email has been successfully added to our mailing list.

×
0.0070339976553341 0.0121141070730755 0.0261821023837437 0.0218835482610396 -0.0265728800312622 -0.0363423212192263 -0.0769831965611567 -0.149667838999609
Stock impact report

Immunome's experimental drug meets main goal in late-stage study [Yahoo! Finance]

Immunome, Inc. (IMNM) 
Company Research Source: Yahoo! Finance
The oral drug, varegacestat, is ?being tested ?in patients with desmoid tumors, also known ?as aggressive fibromatosis or desmoid-type fibromatosis, that are aggressive non-metastatic ?soft tissue tumors that ?are prone to recurrence. The trial showed varegacestat significantly improved progression-free survival compared with placebo, cutting the risk ?of disease progression ?or death ?by 84%. Immunome plans to file for U.S. approval ?in the ?second quarter of 2026. Shares of cancer drug developer ?were up 30% in premarket ?trading. (Reporting by Siddhi Mahatole ?in Bengaluru) Show less Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for IMNM alerts
Opt-in for
IMNM alerts

from News Quantified
Opt-in for
IMNM alerts

from News Quantified